Brinker Capital Investments LLC Trims Stake in Meridian Bioscience, Inc. (NASDAQ:VIVO)

Brinker Capital Investments LLC reduced its holdings in shares of Meridian Bioscience, Inc. (NASDAQ:VIVOGet Rating) by 12.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 32,225 shares of the company’s stock after selling 4,757 shares during the period. Brinker Capital Investments LLC owned about 0.07% of Meridian Bioscience worth $1,016,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Great West Life Assurance Co. Can increased its holdings in Meridian Bioscience by 25.7% during the third quarter. Great West Life Assurance Co. Can now owns 54,154 shares of the company’s stock valued at $1,706,000 after buying an additional 11,059 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of Meridian Bioscience by 98.9% in the third quarter. SG Americas Securities LLC now owns 43,010 shares of the company’s stock worth $1,356,000 after purchasing an additional 21,382 shares in the last quarter. Redhawk Wealth Advisors Inc. purchased a new stake in shares of Meridian Bioscience in the third quarter worth $1,195,000. Assenagon Asset Management S.A. increased its stake in shares of Meridian Bioscience by 55.6% in the third quarter. Assenagon Asset Management S.A. now owns 280,426 shares of the company’s stock worth $8,842,000 after purchasing an additional 100,256 shares in the last quarter. Finally, Strs Ohio increased its stake in shares of Meridian Bioscience by 61.2% in the third quarter. Strs Ohio now owns 26,600 shares of the company’s stock worth $838,000 after purchasing an additional 10,100 shares in the last quarter. 89.72% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on VIVO. William Blair reissued a “market perform” rating on shares of Meridian Bioscience in a research note on Friday, November 25th. StockNews.com cut shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a research note on Saturday, November 19th.

Meridian Bioscience Stock Performance

VIVO opened at $33.74 on Monday. The stock has a market capitalization of $1.48 billion, a price-to-earnings ratio of 34.78 and a beta of 0.26. The company has a fifty day moving average of $32.74 and a 200 day moving average of $32.44. Meridian Bioscience, Inc. has a fifty-two week low of $19.91 and a fifty-two week high of $34.38. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.46 and a current ratio of 3.63.

Meridian Bioscience (NASDAQ:VIVOGet Rating) last posted its earnings results on Tuesday, November 22nd. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.05. The company had revenue of $65.68 million during the quarter, compared to analysts’ expectations of $67.45 million. Meridian Bioscience had a net margin of 12.70% and a return on equity of 16.74%. As a group, sell-side analysts forecast that Meridian Bioscience, Inc. will post 0.83 earnings per share for the current fiscal year.

About Meridian Bioscience

(Get Rating)

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H.

Featured Stories

Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience, Inc. (NASDAQ:VIVOGet Rating).

Institutional Ownership by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.